Stockwinners Market Radar for September 03, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:23 EDT Allena Pharmaceuticals files for Chapter 11 bankruptcy - In a regulatory filing, Allena Pharmaceuticals disclosed that on September 2, after considering all strategic alternatives, the company filed a voluntary petition for relief under the provisions of Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. In connection with this Chapter 11 filing, the company has appointed Matthew Foster as the company's Chief Restructuring Officer, effective as of September 2, and has engaged Mr. Foster's firm, Sonoran Capital Advisors, LLC, to provide services to the company in connection with its Chapter 11 case. The company intends to continue to operate its business at a reduced level as a "debtor-in-possession" under the jurisdiction of the court and in accordance with the applicable provisions of the code and orders of the court. In connection with the Chapter 11 filing, the company has engaged SSG Advisors, LLC in connection with any restructuring transaction or asset sale transaction arising under the Chapter 11 case. Any sale of assets would be subject to review and approval of the court, compliance with agreed upon and court-approved bidding procedures allowing for the submission of higher and better offers, and other agreed-upon conditions. "The company currently expects that the Chapter 11 filing will result in, among other things, the cancellation or extinguishment of all outstanding shares of the company's capital stock without any payment or other distribution on account of those shares," Allena stated.

17:45 EDT Allena Pharmaceuticals Inc trading resumes

17:35 EDT PVH Corp. to replace Hudson Pacific in S&P 400 at open on 9/19

17:29 EDT Outfront Media to replace Fossil in S&P 600 at open on 9/19

17:27 EDT American Eagle to replace CalAmp in S&P 600 at open on 9/19

17:26 EDT Dynatrace to replace American Eagle in S&P 400 at open on 9/19

17:24 EDT Hudson Pacific to repalce American Public Education in S&P 600 at open on 9/19

17:22 EDT PVH Corp. to repalce Hudson Pacific in S&P 400 at open on 9/19

17:19 EDT Invitation Homes to replace Penn Entertainment in S&P 500 at open on 9/19

17:18 EDT CoStar Group to replace PVH Corp. in S&P 500 at open on 9/19

17:11 EDT Jiya Acquisition receives Nasdaq non-compliance notification - Jiya Acquisition announced that on August 23, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market advising the company that the company did not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ had not yet received the company's Quarterly Report on Form 10-Q for the period ended June 30, 2022. NASDAQ informed the company that it had until October 24, 2022 to submit a plan to regain compliance with respect to this delinquent report. The company filed its Form 10-Q on August 31, 2022. As a result of the filing, on September 1, 2022, NASDAQ confirmed that the company is no longer required to submit a plan to regain compliance.

16:32 EDT NanoVibronix receives Nasdaq listing determination - NanoVibronix announced that, on August 30, 2022, the company received notice from the Nasdaq Listing Qualifications Staff indicating that, based upon the company's continued non-compliance with Nasdaq's minimum bid price requirement as of August 29, 2022, the company securities would be subject to delisting unless the company timely requests a hearing before the Nasdaq Hearings Panel. The company plans to timely request a hearing, which request will stay any further action by the Staff at least pending the issuance of the Panel's decision following the hearing and the expiration of any extension that may be granted by the Panel.

16:31 EDT UBS, Wealthfront mutually agree to terminate merger agreement - UBS and Wealthfront have mutually agreed to terminate their merger agreement, initially announced January 26, under which Wealthfront was to be acquired by UBS Americas Inc. UBS will purchase a $69.7M note convertible into Wealthfront shares. UBS remains committed to its growth plans in the US and will continue the build-out of its digital wealth management offering.

16:13 EDT Warrior Technologies Acquisition Company (Class A Stock) trading halted, news pending

16:08 EDT BCE's Bell to acquire Distributel, terms not disclosed - Bell, a wholly owned subsidiary of BCE Inc., and Distributel announced that Distributel intends to join the Bell group of companies to "support its growth strategy in the residential and business segments for Internet services." The companies added: "With Bell's investment, Distributel will benefit from expanded resources and access to technology required to support the next stage in its business growth and to continue to enhance the services it already successfully delivers to customers." Upon the acquisition close, Distributel will continue to operate independently and existing operations will continue under the leadership of Matt Stein, CEO of Distributel. The details of the transaction were not disclosed and the transaction is subject to regulatory approvals. Reference Link

16:05 EDT Ra Medical Systems receives NYSE American notice - Ra Medical Systems announced that on August 31, 2022, it received a notice that the NYSE American LLC has determined the company's securities have been selling at a low price per share for a substantial period of time. Pursuant to Section 1003(f)(v) of the NYSE American Company Guide, the company's continued listing is predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within a reasonable period of time, which the NYSE American has determined to be no later than February 28, 2023.

15:18 EDT E. coli outbreak at Wendy's grows to 97 people, six states - The Centers for Disease Control and Prevention said yesterday that it is continuing to collect different types of data to identify the food source of a multistate outbreak of E. coli infections at Wendy's. "A specific food has not yet been confirmed as the source of this outbreak, but many sick people reported eating burgers and sandwiches with romaine lettuce at Wendy's restaurants before getting sick," the agency said in a statement. Since its last update on August 25, three more illnesses have been reported to the CDC. As of August 31, a total of 97 people infected with the outbreak strain of E. coli have been reported from six states. Sick people range in age from 3 to 94 years, with a median age of 22 years, and 55% are male. Of 81 people with information available, 43 have been hospitalized and 10 developed hemolytic uremic syndrome, a serious condition that can cause kidney failure. No deaths have been reported. "The true number of sick people in this outbreak is likely higher than the number reported, and the outbreak may not be limited to the states with known illnesses," cautioned the CDC. Shares of Wendy's are little changed at $19.36 in afternoon trading. Reference Link

14:01 EDT Kaltura rejects K1 and Panopto's unsolicited acquisition proposal - Kaltura announced that its board of directors, after "a careful and thorough review conducted in consultation with its independent financial and legal advisors," has unanimously determined that the previously disclosed non-binding, unsolicited proposal received from Panopto, a private company owned by K1 Investment Management, in which Panopto would acquire all of the company's outstanding common stock of Kaltura at a purchase price of $3.00 per share in cash, significantly undervalues Kaltura and therefore is not in the best interests of shareholders. In connection with the proposal, the board issued the following statement: "Kaltura's Board of Directors is open to all opportunities to maximize shareholder value and is fully committed to acting in the best interests of Kaltura and our shareholders. After careful review and consideration, we concluded that the K1 and Panopto proposal significantly undervalues Kaltura and does not recognize the strength of our business today, nor our compelling future prospects, and as such is not in the best interest of our shareholders. We believe strongly in our strategy and our ability to generate substantial long-term value for shareholders, as well as in our outlook for returning to profitable growth, and have recently taken cost-reduction and re-organization measures to accelerate it."

13:58 EDT Novavax says Swissmedic authorizes Nuvaxovid for teens, as booster for adults - Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid COVID-19 vaccine in Switzerland for active immunization to prevent COVID-19 caused by the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, in adolescents aged 12 through 17 and as a heterologous and homologous booster dose for adults aged 18 and older. "We are pleased to offer the first protein-based COVID-19 vaccine for use both in adolescents and as a booster in adults in Switzerland. As we continue to explore best practices for managing COVID-19 long term, we have ongoing trials further exploring Nuvaxovid's efficacy and safety as a booster and preclinical data suggest that our vaccine induces immune response against Omicron variants, including BA.4/5," said Stanley Erck, President and CEO of Novavax.

13:20 EDT Vertex announced expanded FDA approval of Orkambi - Vertex Pharmaceuticals announced the Food and Drug Administration approved expanded use of Orkambi to include children with cystic fibrosis ages 12 to less than 24 months who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. Orkambi was previously approved by the FDA for use in people withcystic fibrosis ages two years and older with two copies of the F508del mutation.

12:56 EDT Aurora Innovation up 15% to $2.42 after Bloomberg report

12:17 EDT Amylyx announces posting of briefing documents for second FDA AdCom on AMX0035 - Amylyx Pharmaceuticals announced that the U.S. Food and Drug Administration posted briefing documents for the reconvened Peripheral and Central Nervous System Drugs Advisory Committee, or PCNSDAC, meeting to review the New Drug Application for AMX0035 for the treatment of amyotrophic lateral sclerosis, or ALS. The second meeting of the PCNSDAC for the AMX0035 NDA is scheduled for 12:00 p.m. ET on Wednesday, September 7. "The company is not responsible for the content of, nor the statements made in, the briefing materials that were prepared by the FDA," Amylyx noted. The PCNSDAC previously met on March 30, 2022 to discuss the NDA for AMX0035 for the treatment of ALS. The Prescription Drug User Fee Act, or PDUFA, target action date for the NDA is September 29, 2022, which was extended by the FDA to allow more time to review additional analyses of data from the company's clinical studies, Amylyx said. The briefing materials and webcast information can be accessed [here.]:[https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-7-2022-meeting-peripheral-and-central-nervous-system-drugs-advisory-committee-meeting]

12:11 EDT Profound Medical says CPT Category 1 application for TULSA withdrawn - Profound Medical provided a U.S. reimbursement update for Transurethral Ultrasound Ablation, performed with its TULSA-PRO system. Further to the Company's press release of August 4, 2022, the Current Procedural Terminology Category 1 application for TULSA has been withdrawn for consideration at the upcoming September 2022 CPT Editorial Panel Meeting. Profound anticipates that an updated application, which will include 2022 utilization data, will be submitted at the appropriate time in 2023. In the meantime, U.S. hospitals performing the TULSA procedure on Medicare patients are generally utilizing an existing temporary 'C' code established by the U.S. Centers for Medicare and Medicaid Services for the Hospital Outpatient Prospective Payment System, C9734. In July 2022, CMS released its proposed OPPS reimbursement rule for calendar year 2023. The proposed rule would increase reimbursement to a hospital billing under C9734 by approximately 5% to $13,274. Comments on the proposed rule are due by September 30, 2022 and, once finalized, the policies and payment rates in the final rule will take effect on January 1, 2023.

12:01 EDT Amylyx sinks after FDA posts briefing document AMX0035 panel meeting - Shares of Amylyx are sinking in Friday trading after the FDA posted a briefing document that discusses updates to the information supporting the marketing application of AMX0035 for the treatment of amyotrophic lateral sclerosis, or ALS. The FDA is "reconvening the committee to continue discussion of the application in the context of the additional analyses and data submitted by the applicant," the document stated. The Peripheral and Central Nervous System Drugs Advisory Committee, or PCNS, meeting is scheduled to be held on September 7. Reference Link

12:00 EDT Direxion Daily Gold Miners Bear 3X ETF falls -8.0% - Direxion Daily Gold Miners Bear 3X ETF is down -8.0%, or -$2.24 to $25.95.

12:00 EDT Smartsheet rises 13.0% - Smartsheet is up 13.0%, or $4.02 to $34.84.

12:00 EDT Borr Drilling rises 13.1% - Borr Drilling is up 13.1%, or 52c to $4.48.

11:53 EDT Amylyx Pharmaceuticals trading halted, volatility trading pause

11:23 EDT Walgreens says now offering appointments for updated COVID-19 boosters - Walgreens (WBA) announced that it now offers updated COVID-19 Pfizer (PFE) and Moderna (MRNA) boosters to eligible individuals aged 12 years and older following authorization from the Food and Drug Administration and new guidance from the Centers for Disease Control and Prevention. Scheduling an appointment is preferred and is available starting today for vaccinations, said Walgreens, which notes that additional appointments will be added daily as select Walgreens stores begin to receive the updated COVID-19 boosters.

11:08 EDT Samsung informing U.S. customers about cybersecurity incident - Samsung posted "an important notice regarding U.S. customer information" to its corporate website, in which the company states in part: "Today, we are taking a moment to inform our customers that we recently discovered a cybersecurity incident that affected some of their information. We want to assure our customers that the issue did not impact Social Security numbers or credit and debit card numbers, but in some cases, may have affected information such as name, contact and demographic information, date of birth, and product registration information. The information affected for each relevant customer may vary. Samsung detected the incident and has taken actions to secure the affected systems. As part of our ongoing investigation, we have engaged a leading outside cybersecurity firm and are coordinating with law enforcement. We are notifying customers to make them aware of this matter... We deeply regret any concern or inconvenience this incident may have caused to our valued customers." Reference Link

10:00 EDT Vipshop falls -6.3% - Vipshop is down -6.3%, or -73c to $10.78.

10:00 EDT Oxford Industries falls -8.4% - Oxford Industries is down -8.4%, or -$8.58 to $93.85.

10:00 EDT Borr Drilling rises 8.6% - Borr Drilling is up 8.6%, or 34c to $4.30.

09:47 EDT Scor ADR falls -5.5% - Scor ADR is down -5.5%, or -$1.43 to $24.60.

09:47 EDT Tilly's falls -7.0% - Tilly's is down -7.0%, or -51c to $6.82.

09:47 EDT Braskem rises 7.6% - Braskem is up 7.6%, or 88c to $12.46.

09:43 EDT ShiftPixy trading resumes

09:39 EDT bioAffinity Technologies Inc trading resumes

09:37 EDT Shuttle Pharmaceuticals Inc trading resumes

09:32 EDT Shuttle Pharmaceuticals Inc trading halted, volatility trading pause

09:26 EDT Vita Coco partners with Beautiful Destinations for World Coconut Day - Vita Coco is giving consumers the chance to participate in a collective fundraising initiative to give back to coconut farming communities this World Coconut Day. Vita Coco partnered with Beautiful Destinations to produce short-form video content for the Vita Coco Project, the brand's social impact program that empowers coconut farming communities around the world.

09:20 EDT Lexaria Bioscience appoints Catherine Turkel to board of directors - Lexaria Bioscience announced that Catherine Turkel, PharmD, PhD has joined the board of directors of Lexaria Bioscience Corp. She was Founder and CEO of Nezee Therapeutics and served as President and R&D head at Novus Therapeutics.

09:05 EDT Nano Labs receives Nasdaq panel's decision to grant continued listing request - Nano Labs announced that the Company received a letter from the Nasdaq Hearings Panel, indicating its decision to grant the Company's request to continue its listing on the Nasdaq Stock Market, subject to the condition that the Company will demonstrate compliance with Listing Rule 5210(k)(i) on or before January 16, 2023. On July 19, 2022, the Company received a staff determination letter from the Listing Qualifications Department of Nasdaq notifying the Company of the determination of the Nasdaq staff to delist the Company's securities from The Nasdaq Global Market because of the Company's failure to demonstrate compliance with the requirement that the gross offering proceeds be at least $25 million as outlined in Listing Rule 5210(k)(i). Following receipt of the Letter, the Company, through counsel, appealed the Staff's determination to the Panel and attended a hearing before the Panel on August 25, 2022. During the Exception Period, the Company is required to provide prompt notification of any significant events that occur during this time that may affect the Company's compliance with Nasdaq requirements, including, but not limited to, any event that may call into question the Company's ability to meet the terms of the exception granted.

09:04 EDT ReneSola announces repurchase agreement with ReneSola Singapore - ReneSola announced that the company has entered into a securities repurchase agreement with ReneSola Singapore Pte. Ltd., one of the company's major shareholders, pursuant to which, among other things, the company will repurchase from ReneSola Singapore 70,000,000 shares represented by 7,000,000 ADSs at a price of 60c per share, totaling $42M through a privately negotiated transaction. ReneSola Singapore will be subject to a 90-day lock-up restriction with respect to its remaining share ownership of the company and other customary covenants. Shah Capital will purchase 10,000,000 shares represented by 1,000,000 ADSs from ReneSola Singapore at a price of 60c per share or $6.00 per ADSs. Affiliates of ReneSola Singapore will resign from their offices as legal representatives, directors, and officers of the Company and its subsidiaries shortly after the closing of the repurchase transaction. Crystal Li and Maggie Ma will resign from the board of directors of the company immediately upon closing of the repurchase transaction. Crystal Li will also resign from her executive role as the vice president of investment of the company simultaneously. In connection with and effective upon the closing of the repurchase transaction, the currently effective investor rights agreement dated as of October 2, 2019 by and among the Company, Xianshou Li, ReneSola Singapore, Shah Capital Opportunity Fund LP and certain other parties named therein will be terminated. The company will enter into an amended and restated investor rights agreement separately with Shah Capital. The terms of the amended and restated investor rights agreement are substantially the same as those under the previous investor rights agreement, except that (i) Shah Capital, subject to certain minimum shareholding requirements and a step-down mechanism, is entitled to nominate three designees for election and/or appointment as directors of the company, and (ii) the board of directors of the company is entitled to jointly nominate for election and/or appoint one director.

09:02 EDT CleanSpark reports 395 bitcoin mined in August - CleanSpark released its unaudited bitcoin mining and operations update for the calendar year-to-date ending August 31, 2022. "We set out at the beginning of the year to become a top five publicly traded bitcoin mining company and with our outstanding operational performance in 2022 we can say we are now firmly in that category. We now own and operate three campuses in Georgia. Our hashrate has tripled over the last year. We are on a trajectory to nearly double that in less than half the time it took us to get from 1 EH/s to 3 EH/s. And we are about to hire our 100th employee. I'm extremely proud of our team and their tremendous work," said Zach Bradford, CEO. Bitcoin Mining & Operations Update: Bitcoin mined in August: 395, up 109% from August 2021; Calendar year-to-date bitcoin mined: 2,642; Total BTC holdings as of August 31: 526; Total BTC converted for operations and growth in August: 388, 9% less than July 2022; Currently deployed fleet of over 36,800 latest-generation bitcoin miners with a hashrate of 3.4 EH/s, up 19% from July 2022 and 331% from August 2021; The Company funded growth and operations through the sale of 388 bitcoins in August 2022 at an average of approximately $23,088 per BTC. Sales of BTC equated to proceeds of approximately $8.9 million. August daily BTC mined reached a high of 13.39.

08:52 EDT Big River shareholders vote in favor of acquisition by Aura Minerals - Aura Minerals informed that Big River Gold announced that the requisite majorities of each class of shareholders voted in favour of the proposed scheme of arrangement, pursuant to which Borborema, an indirect wholly-owned subsidiary of Aura will acquire all of the shares in Big River. As previously disclosed, Aura will hold its interest in BidCo through an intermediate holding company with Dundee Resources which agreed, subject to certain limited conditions, to receive shares in JVCo, in lieu of the cash consideration, in order to indirectly maintain an equity interest in Big River and form a joint venture with Aura. Big River will now seek approval of the Scheme from the Court at the Second Court Hearing. If the Court approves the Scheme at the Second Court Hearing, it is expected that the Scheme will take effect on September 9, 2022. Scheme implementation is expected to occur on September 20, 2022, subject to the satisfaction or waiver of the remaining conditions precedent to the Scheme, including approval by the Court at the Second Court Hearing.

08:45 EDT Nikon offers to acquire SLM Solutions for EUR 20 per share - Nikon Corporation (NINOY) announced the signing of an investment agreement with SLM Solutions Group AG (SLGRF) and in conjunction, Nikon AM. AG, a direct subsidiary of Nikon, announced its decision to launch a voluntary public takeover offer for the acquisition of all outstanding shares of SLM on a fully diluted basis. SLM shareholders will be offered a cash consideration of EUR 20.00 per share. The offer price represents a premium of 83.7% to the XETRA volume-weighted average share price of SLM in the last three months prior to and including September 1, the companies noted. In addition, the bidder announced its decision to launch a separate public offer for the acquisition of certain convertible bonds issued by SLM. The total transaction value is EUR 622M. The takeover offer will not be subject to a minimum acceptance threshold. Completion is contingent on foreign investment control clearances, no insolvency of SLM, and no capital measures other than for certain exceptions.

08:39 EDT PolyPid says SHIELD I study did not achieve primary endpoint - PolyPid announced top-line results from the SHIELD I Phase 3 study of D-PLEX100 for the prevention of surgical site infections in abdominal surgery. SHIELD I is a prospective, multinational, randomized, double-blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with standard of care compared to a SoC alone arm, in the prevention of post-abdominal surgery incisional infection. The primary endpoint of the trial is the combination of incisional SSIs and mortality as measured by the proportion of subjects with either an SSI event, as determined by a blinded and independent adjudication committee, or mortality for any reason within 30 days post-surgery. The SHIELD I study is designed to demonstrate at least a 50 percent reduction in incisional SSIs in the D-PLEX100 treatment arm compared to the control arm, with 90 percent power and a maximum alpha level of 0.0487. A total of 977 patients were randomized into the study, consisting of 488 subjects in the D-PLEX100 treatment arm and 489 patients in the control arm. In the Intent to Treat population, the local administration of D-PLEX100 and SoC resulted in a decrease in SSIs and mortality of 23 percent compared to SoC alone. Within the first 30 days post-surgery, there were 15 deaths in the SoC treatment arm, as compared to 11 in the D-PLEX100 treatment arm. The local administration of D-PLEX100 as compared to SoC alone also did not achieve statistical significance on the key secondary endpoint evaluating SSI events within 30 days post-abdominal index surgery. In a pre-specified subgroup ITT analysis requested by the U.S. Food and Drug Administration of a total of 423 subjects with incision lengths greater than20 centimeters, the local administration of D-PLEX100 resulted in a statistically significant reduction of 54 percent on the primary endpoint, compared to SoC alone. Within the first 30 days post-surgery, SSIs decreased from 8.5% in the SoC treatment arm, as compared to 4.2% in the D-PLEX100 treatment arm. There were no safety concerns raised by the independent Data Safety Monitoring Board in SHIELD I. PolyPid intends to present the full top-line results from SHIELD I at a future medical meeting. The Company's second Phase 3 trial of D-PLEX100 for the prevention of SSIs in abdominal surgery, SHIELD II, which incorporates broader eligibility criteria, is ongoing and has enrolled over 200 subjects to date. Based on the overall data generated in SHIELD I, PolyPid intends to discuss the results with the FDA and evaluate the appropriate next steps for SHIELD II.

08:32 EDT PolyPid trading halted, news pending

08:12 EDT Arcutis Biotherapeutics appoints Neha Krishnamohan to board of directors - Arcutis Biotherapeutics (ARQT) announced that Neha Krishnamohan has been appointed to the Arcutis Board of Directors and as a member of the audit committee. Following the appointment, the Board will be composed of 10 directors. Krishnamohan is currently the CFO and EVP of Corporate Development at Kinnate Biopharma (KNTE).

08:09 EDT Genetic Technologies provides update on U.S. operations, payer engagement - Genetic Technologies reports commercial progress in the USA strategic operations with the following updates: Strategic Highlights: Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives; Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions; Commercial evaluations underway at 10 US medical/family practices; Re-engagement with 1,600 previous geneType US customers; Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders Summit in Boston; Online ordering of geneType Multi-Risk Test with Telehealth support established; Melbourne laboratory receives US CLIA certification as a "High Complexity Laboratory"; African American ethnicity validation and research collaboration with Washington State University well underway; establishment of a new US operations team dedicated to EasyDNA product sales. The completion of a Budget Impact Model by Boston based consultant, Alva10, has allowed the company to identify a target list of some 30 payers. These range from commercial insurers covering millions of lives to smaller employer groups and with the support of the Market Access team at Alva10 we have active discussions with 11 payers. The goal is to establish initial coverage and reimbursement for the geneType Breast Cancer Risk Assessment Tests and the introduce the Multi-Risk test more broadly. The BIM demonstrated that the introduction of geneType for Breast cancer would save the US payer system US$1.4b annually and resulting in a significant improvement in health outcomes for women at elevated risk of developing breast cancer. In addition, reimbursement and payer coverage will provide GTG with a substantial commercial success. Alva10 is continuing to assist GTG with a market access strategy focussing on engagement with payers. Gaining reimbursement for the breast cancer risk assessment test will also provide a template for the other risk assessment tests in the Multi-Risk portfolio starting with colorectal cancer. Since the launch of the geneType Multi-Risk test, the US GTG team have reported commercial progress. The company is in advanced discussions with two Concierge Medicine networks representing 19 medical centres and the US Team has initiated a reengagement strategy targeting 1,600 previous geneType US customers. The acquisition and integration of EasyDNA has provided an ideal opportunity to broaden patient and clinician access to the geneType Multi-Risk Assessment Test. The test is now available with Telehealth support through the EasyDNA website. Commenting on the forward outlook, Simon Morriss stated "We are very pleased with the progress made over this quarter in achieving TGA approvals for the Multi-Risk Test. We now have three brands, geneType, EasyDNA and AffinityDNA anchoring future revenues to seize a multi-Billion-dollar market opportunity with the most comprehensive portfolio of testing available for individuals and animals. Our focus remains on the commercialization opportunities, establishing the centres of excellence with our geneType Hub strategy. Our US plans continue to be focussed on concierge medicine groups and gaining coverage from the US payer system. Driving revenue growth by leveraging the EasyDNA and AffinityDNA brands with further investment in R&D to enhance our Multi-Risk Test offering continuing to remain at the cutting edge of genetic testing and preventative health."

08:07 EDT Iveric bio reports inducement grants under Nasdaq Listing Rule - IVERIC bio reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were approved by the Company's compensation and talent strategy committee pursuant to a delegation by the Company's board of directors and were made as a material inducement to each employee's acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The stock options have an exercise price of $9.89 per share, equal to the closing price of Iveric Bio's common stock on September 1, 2022.

07:38 EDT Equinor completes Russian exit - In a press release, Equinor said, "On 25 May 2022, Equinor announced its exit from the four joint ventures with Rosneft as well as the signing of an agreement to leave the Kharyaga project. Equinor can now confirm that the full exit from Kharyaga has also been completed. As part of the exit from Kharyaga, Equinor has in compliance with applicable sanctions covered decommissioning liabilities accrued and owed by Equinor over the years. Following the exit from Kharyaga, Equinor has no remaining assets or projects in Russia." Reference Link

07:31 EDT CME Group reports August ADV growth of 22% - CME Group reported its August 2022 market statistics, showing average daily volume increased 22% to 21.2M contracts during the month.

07:08 EDT Precision BioSciences announces senior leadership organizational changes - Precision BioSciences announced promotions and organizational changes that impact responsibilities within the company's senior leadership team reporting to Michael Amoroso, Chief Executive Officer, CEO. Cindy Atwell, formerly Senior Vice President of Business Development and Alliance Management has been promoted to Chief Business Officer and will continue to oversee the Business Development and Alliance functions with added responsibility for Project and Portfolio Management. Jeff Smith, Ph.D., co-founder and formerly Chief Technology Officer, has been promoted to Chief Research Officer and will assume responsibility for the management and direction of the company's research programs and report directly to the CEO. Derek Jantz, Ph.D., co-founder and Chief Scientific Officer will focus his time partnering with Michael Amoroso in formulating company strategy and managing relationships with external stakeholders, including current and potential collaboration partners. In addition, Dr. Jantz informed the Board of Directors that he was stepping away from the Board to focus his time, effort and energy on his new role, which reduces the number of management members serving on the Board and strengthens the company's corporate governance

07:03 EDT Microbot Medical on track to commence GLP pre-clinical trial later in September - Microbot Medical announced, as part of the preparation for its anticipated U.S. Food and Drug Administration and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a research laboratory to conduct the Company's GLP pre-clinical trial. The comprehensive trial, which is anticipated to commence later this month, will be performed by a team of global leaders in the endovascular space at a lab with FDA approved levels of planning, controlling, monitoring and reporting. The Company expects the results of the GLP pre-clinical trial will further validate the outcomes from multiple prior animal feasibility studies performed.

06:50 EDT Amazon introduces Warehousing & Distribution service for seller storage - In a Wednesday press release, Amazon announced its Warehousing & Distribution service, which provides "low-cost, long-term storage" for sellers in Amazon distribution centers. The company said, "As a continuation of Amazon's multiyear investment in its warehousing and distribution network to support sellers and better serve customers, we are introducing a new solution that enables sellers to use new, purpose-built facilities for bulk inventory storage and automated distribution. Amazon Warehousing & Distribution addresses critical supply chain challenges and helps sellers grow and manage their business while significantly cutting costs. AWD is also one of the many new offerings we will be sharing more about at Amazon Accelerate, our annual seller conference taking place September 14-15...With this simple pay-as-you-go service, sellers are free from the time-consuming, cumbersome process of moving inventory from upstream facilities to Amazon fulfillment centers. AWD makes the promise of supply chain as a service a reality and is specifically designed to solve inventory management challenges and deliver operational efficiencies." Reference Link

06:43 EDT House Republicans demand Zuckerberg hand over FBI warnings on Hunter Biden - In a Thursday letter to Meta Platforms CEO Mark Zuckerberg, 35 House Republicans said, "Shortly before the 2020 presidential election, Facebook suppressed an explosive New York Post article detailing how Hunter Biden used the position and influence of his father, now- President Biden, for personal gain, with the apparent awareness of President Biden. We wrote to Facebook at the time with important questions about Facebook's knowing suppression of First Amendment-protected activity.1 In March 2022, after other outlets finally acknowledged the veracity of the Biden family's influence-peddling scheme, we wrote again with additional questions about Facebook's actions to suppress critical election-related information. Facebook has never provided complete responses to these letters and, in the months since, has avoided any real accountability for its actions in interfering with election-related public discourse. Recently, you described how Facebook's censorship of the allegations about the Biden family before the 2020 election followed a message from the Federal Bureau of Investigation that Facebook "should be on high alert" for "Russian propaganda." You acknowledged that this official alert from the FBI is what led to Facebook reducing the circulation of the Post's reporting on its platform, preventing Americans from fully understanding highly relevant allegations about President Biden's awareness of and involvement in his family's influence- peddling scheme. Accordingly, we write to request additional information about Facebook's actions to interfere in free and fair election-related public discourse." Reference Link

06:31 EDT Cenntro Electric to expand Logistar all-electric commercial product line - Cenntro Electric Group announced another expansion of the Logistar series, the new Logistar 260. The All-Electric commercial van is scheduled for initial deliveries in the first quarter of 2023 to Europe followed by launches in Asia, the Caribbean, and South American markets. The load volume, payload and range of the Logistar 260 will be targeted for a wide range of applications in the trades, couriers, express and parcel services, logistics solutions, and facility management. The LS 260 is expected to pass all homologation tests in accordance with European Union standards and requirements and receive EU type approval at the end of 2022.

06:19 EDT Electrolux to exit Russia, divests business to local management - As previously communicated Electrolux paused its operations in Russia when the war in Ukraine commenced. Electrolux has now decided to exit Russia and divest the business to local management through a sale of its Russian subsidiary. A capital loss of approximately SEK 350m will be recorded as a non-recurring item affecting the operating income for Business Area Europe in the third quarter 2022. "Russia's invasion of Ukraine and the following sanctions have made it impossible for Electrolux to continue its business in the country. The decision to divest the Russian business to local management is intended to enable a responsible and controlled exit," the company said. The divested company will continue to service appliances previously sold by Electrolux in Russia. Electrolux has no production in Russia and will not supply any appliances to the divested company. The final operating income and cash flow effects will be determined by the balance sheet and exchange rate on the transaction day.

06:01 EDT Bright Scholar regains compliance with NYSE minimum price requirement - Bright Scholar Education announced that based upon a notice the Company received on September 1, 2022 from the New York Stock Exchange, the NYSE, the Company has regained compliance with the NYSE's continued listing standard for share prices. On March 25, 2022, the NYSE notified the Company of its non-compliance with the NYSE's price criteria for continued listing standard because, as of March 24, 2022, the average closing price of the Company's American Depositary Shares was less than US$1.00 per ADS over a consecutive 30 trading-day period. On September 1, 2022, the Company received a confirmation from the NYSE that a calculation of the Company's average ADS price for the 30-trading days ended August 31, 2022, indicated that the Company's ADS price was above the NYSE's minimum requirement of US$1.00 based on a 30-trading day average. Accordingly, the Company is no longer considered below the US$1.00 continued listing criterion. As a result, the Company has regained compliance within the prescribed time, and the ADSs will continue to be traded on the NYSE, subject to the Company's continued compliance with all applicable continued listing criteria.

05:53 EDT Vaalco Energy announces departure of Chief Compliance Officer Michael Silver - Vaalco Energy (EGY) announced that Michael Silver, its Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer, has advised of his intention to leave Vaalco to pursue other interests. Silver will remain with the company for a transitional period to facilitate consummation of the proposed arrangement with TransGlobe Energy (TGA). The company has launched an executive search to find a replacement for the position.